

Table S1. Characteristics of 90 ANC/L&D sites delivering PMTCT services in Kinshasa, Democratic Republic of Congo as of 2013

| | N (%) |
|---|----------------|
| Administration | |
| Catholic | 17 (8.0) |
| Protestant | 12 (35.1) |
| State | 27 (33.5) |
| Private (for profit or other non-governmental organization) | 34 (23.4) |
| Year basic PMTCT package initiated | |
| 2003 | 5 (5.6) |
| 2004 | 15 (16.7) |
| 2005 | 10 (11.1) |
| 2008 | 6 (6.7) |
| 2010 | 1 (1.1) |
| Not applicable (expanded PMTCT package only) | 53 (58.9) |
| Year expanded PMTCT package fully implemented | |
| 2011 ^a | 44 (48.9) |
| 2012 | 46 (51.1) |
| Year triple-drug ART available ^b | |
| 2012 | 5 (5.6) |
| Never | 85 (94.4) |
| Year HIV-infected clinic volunteer(s) became available | |
| 2010 | 17 (18.9) |
| 2011 | 28 (31.1) |
| Never | 45 (50.0) |
| | Median (IQR) |
| Number of women HIV tested yearly per ANC/L&D site ^c | 797 (573-1184) |
| Number of women identified as HIV-infected yearly per ANC/L&D site ^c | 10 (6-17) |
| Number of pregnancies recorded in register per ANC/L&D site ^d | 21 (7-47) |

Abbreviations: ANC, antenatal care; ART, antiretroviral therapy; C&T, care and treatment; IQR, interquartile range; L&D, labor and delivery; PMTCT, prevention of mother-to-child HIV transmission.

^a Registers and training introduced in 2010; other components of expanded package rolled out in 2011.

^b Triple-drug ART became available at affiliated HIV C&T centers in 2004 (Kalembe Lembe) and 2006 (Bomoi). As of 8/2013, the approximate numbers of patients receiving care were 1800 at Kalembe Lembe and 1200 at Bomoi.

^c Calculated using the ANC/L&D site's entire duration of participation in the UNC-DRC program. From 6/2003 through 6/2013, 439,495 women were tested for HIV during ANC or L&D at the 90 ANC/L&D sites with 6,941 (1.6%) testing positive.

^d Range: 0-273.

Table S2. Profile of HIV-infected women (and their infants) registered at 90 ANC/L&D sites in Kinshasa, Democratic Republic of Congo, 2010 – 2013 ^a

| | N (%) |
|---|--------------|
| Total pregnancies registered ^b | 3190 (100.0) |
| Year of presentation | |
| 2010 | 327 (10.3) |
| 2011 | 1010 (31.7) |
| 2012 | 1154 (36.2) |
| 2013 | 699 (21.9) |
| Age at presentation | |
| <20 | 145 (4.5) |
| 20- <30 | 1245 (39.0) |
| 30- <40 | 1319 (41.3) |
| ≥40 | 131 (4.1) |
| Not recorded | 350 (11.0) |
| HIV at presentation | |
| Previously diagnosed | 929 (29.1) |
| Undiagnosed | 2261 (70.9) |
| Pregnancy stage at presentation ^c | |
| ≤28 weeks | 2104 (65.9) |
| >28 weeks, before labor and delivery | 483 (15.1) |
| Unknown, before labor and delivery | 40 (1.3) |
| Labor and delivery | 563 (17.6) |
| WHO HIV clinical stage at presentation | |
| 1 | 625 (19.6) |
| 2 | 141 (4.4) |
| 3 | 52 (1.6) |
| 4 | 7 (0.2) |
| Not assessed | 2365 (74.1) |
| CD4 test during pregnancy | |
| No | 1805 (56.6) |
| Yes | 1385 (43.4) |
| ≤350 ^d | 635 (45.8) |
| >350 | 676 (48.8) |
| No result | 74 (5.3) |
| Maternal antiretroviral regimen | |
| None | 510 (16.0) |
| Single-dose NVP (with or without ATC/3TC tail) | 602 (18.9) |
| AZT during pregnancy (with or without single-dose NVP + ATC/3TC tail) | 1219 (38.2) |
| Triple-drug ART during pregnancy | 859 (26.9) |

| | |
|--|--------------|
| Referred to Kalembe Lembe or Bomoi (affiliated HIV C&T centers) | |
| No | 1627 (51.0) |
| Not applicable (already receiving HIV C&T) | 710 (22.3) |
| Yes | 853 (26.7) |
| <i>Did not arrive</i> ^e | 288 (33.8) |
| <i>Arrived</i> | 565 (66.2) |
| Pregnancy outcome | |
| Delivered, at program ANC/L&D site | 2033 (63.7) |
| <i>Free</i> ^f | 1571 (77.3) |
| <i>Paid</i> | 462 (22.7) |
| Delivered, not at program ANC/L&D site | 103 (3.2) |
| Delivered, location unknown | 88 (2.8) |
| Miscarriage | 50 (1.6) |
| Mother died | 9 (0.3) |
| Transferred to non-affiliated site, moved, or voluntarily withdrew | 41 (1.3) |
| Lost to follow-up | 627 (19.7) |
| Projected still pregnant at study end | 239 (7.5) |
| <hr/> | |
| Total liveborn infants ^g | 2132 (100.0) |
| <hr/> | |
| NVP at delivery | |
| No | 135 (6.3) |
| Yes | 1997 (93.7) |
| Visit ≥ one month of age | |
| No | 893 (41.9) |
| Yes | 1239 (58.1) |
| Cotrimoxazole | |
| No | 1010 (47.4) |
| Yes | 1122 (52.6) |
| Extended NVP | |
| No | 677 (31.8) |
| Yes | 1455 (68.2) |
| DNA PCR test | |
| No | 1033 (48.5) |
| Yes ^h | 1099 (51.5) |
| <i>Positive</i> ⁱ | 51 (4.6) |
| <i>Negative</i> | 968 (88.1) |
| <i>No result</i> | 80 (7.3) |

Abbreviations: ANC, antenatal care; ART, antiretroviral therapy; AZT, zidovudine; C&T, care and treatment; L&D, labor and delivery; NVP, nevirapine; WHO, World Health Organization.

^a Data from ANC/L&D sites (two of 90 had zero registered pregnancies) and two affiliated HIV C&T centers. Previously diagnosed women may have received ART from other facilities.

^b In 3121 women: 3052 women had one registered pregnancy; 69 women had two registered pregnancies.

^c If gestational age at registration was not recorded, it was estimated using projected date of delivery and otherwise date of delivery (if available). The median gestational age of women at presentation was 24 weeks (interquartile range, 20-32).

^d Denominator: 1378 women who had a CD4 test during pregnancy.

^e Denominator: 853 women who had been referred to Kalembe Lembe or Bomoi.

^f Denominator: 2033 women who delivered at program ANC/L&D sites.

^g The 2225 documented deliveries yielded 2254 infants (29 sets of twins), 2133 of whom survived birth.

^h 463 of these infants (42.2%) had two or more DNA PCR tests.

ⁱ Denominator: 1098 infants who had a DNA PCR test. The maternal antiretroviral regimens for positive infants were ART (23.5%), AZT (21.6%), single-dose NVP only (41.2%), and none (13.7%), contrasting 36.7%, 41.3%, 20.5%, and 1.6% in negative infants.